In contrast, no differences were found when RCTs were stratified according to the specific SGLT2 inhibitor or the presence or absence of other specific inclusion criteria, such as DM, CKD, or the timing of HF (acute vs. chronic). This evidence concerns the gene SLC5A2 and diabetes mellitus.